February, 20th - 1 year ago
The report "BIOSIMILAR MARKET”: Byproduct (Insulin, Interferon, Human Growth Hormone, Others); By Services (Clinical Trials, Contract Research & Manufacturing Services); By technology (Chromatography, Nuclear Magnetic Resonance Technology, Recombinant DNA Technology, Monoclonal Antibodies Technology); By Applications (Oncology Diseases, Blood Disorders, Growth Hormone Deficiency); By Geography (Asia Pacific, North America, Europe, Middle East and Africa, South America) – Forecast and Estimation (2018-2024). According to Biosimilar market research report, the market size is expected to reach XX Billion by 2024 at a CAGR of XX%. Biosimilar market share is projected to grow during the forecast period owing to high growth in the prevalence of chronic diseases, and less cost biosimilar drugs. Download a free sample report @ https://www.envisioninteligence.com/industry-report/biosimilar-market/ Global biosimilar market segmented on the basis of product, services, technology, applications, and geography. On the basis of products, the market is segmented into insulin, interferon, granulocyte colony stimulating factor, human growth hormone, and some others. Granulocyte colony-stimulating factor is anticipated to have the highest growth as per biosimilar market report because it is cost-effective, the rise in diabetes are the factor for the segment growth. Based on services, the market is classified into clinical trials and contract research & manufacturing services. Clinical trials have the largest biosimilar market value due to low-cost drugs and vaccines that treat chronic disease. Based on application, the biosimilar market is segmented into oncology, blood disorders, chronic & autoimmune diseases, growth hormone deficiency, and others. The oncology and blood disorders are expected to have the largest biosimilar market size due to increase in cancer, high-rated biologics, and less healthcare expenditure are contributing the growth. On basics of technology, the market is categorized into chromatography, recombinant DNA technology, monoclonal antibodies technology, nuclear magnetic resonance technology, and so on. Monoclonal antibodies technology is projected to grow during the forecast period because of treatment procedures for chronic disorders in a single operation. Asia-Pacific is the fastest growing region due to increase in biosimilar market opportunities As per biosimilar market overview, Asia Pacific is projected to be the fastest growing biosimilar market landscape during the forecast period 2018-2024. Key countries which are providing utmost demand for the biosimilar in the Asia Pacific region are China, India, Japan, South Korea, and other economies because of their rise in technologies, less per capita, increase in trading are factors driving the market. The biosimilar market players include Celltrion Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Samsung Bioepis, Pfizer Inc and Teva Pharmaceuticals Industries Ltd.